글로벌 재조합 비당화 단백질 시장 – 2028년까지의 산업 동향 및 예측

재조합 비당화 단백질 시장의 시장 분석 및 통찰력

Data Bridge Market Research는 재조합 비당화 단백질 시장이 2021-2028년 예측 기간 동안 약 7.33%의 CAGR을 보일 것이라고 분석했습니다. 전 세계적으로 감염성 질환의 유병률이 증가하고, 주요 제조업체의 기술 발전에 대한 집중도가 높아지고, 특히 개발도상국에서 의료 인프라 개발에 대한 지출이 증가하는 것이 재조합 비당화 단백질 시장 성장에 기여하는 주요 요인입니다. 따라서 2020년에 1억 9,889만 달러였던 시장 가치는 2028년까지 3억 5,025만 달러로 급증할 것입니다.

재조합 비당화 단백질은 인간 집락 자극 과립구 인자를 함유합니다. 재조합 비당화 단백질은 또한 성장 호르몬, 인슐린 및 인터페론을 함유하여 광범위한 응용 분야에 적합합니다.

인구 중 만성 질환의 유병률의 급증은 재조합 비당화 단백질 시장 성장을 촉진하는 주요 요인 중 하나입니다. 관련 기술을 개발하기 위한 의료 분야의 다양한 혁신과 연구의 출현 증가와 바이오시밀러에 대한 수요의 급증은 재조합 비당화 단백질 시장 성장을 간접적으로 결정하는 요인 중 일부입니다. 도시화 증가, 라이프스타일 변화, 노령 인구의 끊임없는 증가, 개인의 가처분 소득 증가는 수익성 있는 재조합 비당화 단백질 시장 성장 기회를 더욱 창출할 것입니다.

그러나 연구 개발 능력과 관련된 높은 비용은 재조합 비당화 단백질 시장 성장 제약으로 작용할 것입니다. 바이오시밀러 제조와 관련된 복잡성은 재조합 비당화 단백질 시장 성장률을 더욱 탈선시킬 것입니다. 특히 개발도상국의 불리한 규제 및 환불 정책은 재조합 비당화 단백질 시장에 더욱 큰 과제를 안겨줄 것입니다.

This recombinant non-glycosylated proteins market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on recombinant non-glycosylated proteins market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Recombinant Non-Glycosylated Proteins Market Scope and Market Size

The recombinant non-glycosylated proteins market is segmented on the basis of product and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on product, the global recombinant non-glycosylated proteins market has been divided into recombinant human growth hormone, granulocyte colony-stimulating factor, insulin and interferon. Interferon segment is sub-divided into interferon- beta and interferon- alpha.
• Based on the application, the recombinant non-glycosylated proteins market is segmented into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases and other diseases.

Recombinant Non-Glycosylated Proteins Market Country Level Analysis

The recombinant non-glycosylated proteins market is analysed and market size insights and trends are provided by country, product and application as referenced above.

The countries covered in the recombinant non-glycosylated proteins market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the recombinant non-glycosylated proteins market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is because of the prevailing sophisticated level of healthcare facilities, sedentary lifestyle practices and surge in the cases of infectious and chronic diseases. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period owing to the increase in awareness about recombinant non-glycosylated proteins, increased expenditure on healthcare infrastructure and rising personal disposable income.

The country section of the recombinant non-glycosylated proteins market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The recombinant non-glycosylated proteins market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for digital health technologies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the recombinant non-glycosylated proteins market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Recombinant Non-Glycosylated Proteins Market Share Analysis

The recombinant non-glycosylated proteins market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to recombinant non-glycosylated proteins market.

재조합 비당화 단백질 시장 보고서에서 다루는 주요 기업으로는 Novartis AG, Astrazeneca, Pfizer Inc., Sanofi, Amgen Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Mylan NV, Dr. Reddy's Laboratories Ltd., Celltrion Healthcare Co.,Ltd., Biocon., Samsung Biologics., STADA Arzneimittel AG, Merck & Co., Inc., CEVEC Pharmaceuticals GmbH, Genentech, Inc., WOCKHARDT., ACROBiosystems., Mundipharma International Limited 등이 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-46278